NanoViricides, Inc. Presents at FDA Nanotechnology Meeting
Final Draft of Form 10-SB for SEC Submission Completed
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc, (Pink Sheets: NNVC) President and Chairman, Dr. Anil Diwan, presented a talk at the U.S. Food and Drug Administration (FDA) Public Meeting on Nanotechnology in Bethesda, MD on Oct. 10.
“Having this early chance to present important perspectives to the FDA will help us expedite our drug development processes.”
Diwan discussed the nanoviricides technology. “Such high drug efficacies as shown by nanoviricides drugs compared to existing therapies may very well represent a new plateau in anti-viral therapy,” he said. Scientists agreed that it is important to expedite developments that can have a significant impact on public health, such as the nanoviricides technologies.
Diwan also discussed the specific novel characteristics of nanoviricides that make them different from existing small chemicals and biologics that FDA has traditionally worked with. He explained that nanoviricides have unique and significant advantages over other technologies such as combination drug delivery products, nanoparticle technologies among others, that have been widely discussed in scientific literature.
“Nanoviricides have a significant safety edge, because of their unique design and the fact that they are designed to be biodegradable within the body,” Dr. Diwan stated.
Diwan also presented to the FDA on a novel approach to bio-threat response that he calls the “war-like scenario” enabled by the advent of the nanoviricides technology. In this scenario, a nanoviricide drug can be developed as soon as a bio-threat event occurs in the field, whether from bio-terrorism or from natural outbreaks. This can be accomplished even before the pathogen is identified and diagnostic tests can be developed.
For the first time, this approach may enable suppression of epidemics at the very first cluster even before they have a chance to break out further, thus minimizing the threat of a pandemic.
“We are very happy that we had a chance to present our comments to the FDA Nanotechnology task force,” said NanoViricides’ Chief Regulatory Officer Dr. Krishna Menon
NanoViricides’ Chief Executive Officer Dr. Eugene Seymour added, “Having this early chance to present important perspectives to the FDA will help us expedite our drug development processes.”
In other news, NanoViricides announced it has submitted its SEC Form 10-SB and financial statements for final review to the Company’s attorneys and auditors respectively, on Oct 10. “The Company understands that it is critical during this review to make its financial statements available to its shareholders and investors. We plan to file them in a 15c2-11 format on Pinksheets.com by the end of next week,” said NanoViricides CFO, Leo Ehrlich.
About NanoViricides - http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide™ is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.